Published in Curr Opin Nephrol Hypertens on May 01, 2009
Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis (2011) 2.11
Measurement of organ structure and function enhances understanding of the physiological basis of frailty: the Cardiovascular Health Study. J Am Geriatr Soc (2011) 1.87
Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One (2010) 1.08
Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus. Cardiovasc Diabetol (2013) 0.87
Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus. Lupus (2011) 0.84
Estimating glomerular filtration rate in diabetes using serum cystatin C. Clin Biochem Rev (2011) 0.83
Comparison of CKD-EPI Cystatin C and Creatinine Glomerular Filtration Rate Estimation Equations in Asian Indians. Int J Nephrol (2014) 0.82
Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol (2015) 0.82
Coffee consumption and cystatin-C-based estimated glomerular filtration rates in healthy young adults: results of a clinical trial. J Nutr Metab (2011) 0.81
Body mass index and preclinical kidney disease in Indian adults aged 40 years and above without chronic kidney disease. Clin Exp Nephrol (2014) 0.80
Relationship between Systemic and Cerebral Vascular Disease and Brain Structure Integrity in Normal Elderly Individuals. J Alzheimers Dis (2015) 0.80
Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients. Yonsei Med J (2017) 0.75
Kidney Toxicity Induced by 13 Weeks Exposure to the Fruiting Body of Paecilomyces sinclairii in Rats. Toxicol Res (2012) 0.75
Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med (2005) 15.30
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis (2008) 15.04
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33
Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc (1985) 7.02
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med (2006) 6.58
Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis (2002) 6.52
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med (2005) 4.57
Rapid kidney function decline and mortality risk in older adults. Arch Intern Med (2008) 3.54
Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol (2005) 3.48
Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol (2005) 3.28
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem (2004) 2.95
Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med (2007) 2.71
Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis (2008) 2.64
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 2.55
Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem (2001) 2.22
Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med (2008) 2.11
Chronic kidney disease and functional limitation in older people: health, aging and body composition study. J Am Geriatr Soc (2006) 2.04
Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol (2006) 1.92
Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol (2006) 1.91
Cystatin C and subclinical brain infarction. J Am Soc Nephrol (2005) 1.88
Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest (2005) 1.86
Cystatin C and aging success. Arch Intern Med (2008) 1.79
Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol (2005) 1.79
Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation (2004) 1.67
Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care (2008) 1.67
Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology (2006) 1.45
Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med (2005) 1.43
Cystatin C modulates cerebral beta-amyloidosis. Nat Genet (2007) 1.42
Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med (2008) 1.37
Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol (2008) 1.24
Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci (2006) 1.20
Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care (2007) 1.12
Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study. Am J Kidney Dis (2007) 1.05
Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J (2007) 1.04
Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol (2008) 1.00
Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology (2008) 0.99
Cystatin C--a marker of peripheral atherosclerotic disease? Atherosclerosis (2008) 0.95
Cystatin C: research priorities targeted to clinical decision making. Am J Kidney Dis (2008) 0.94
Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol (2007) 0.93
Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke (2007) 0.92
Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail (2008) 0.90
Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med (2001) 0.82
Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med (2005) 15.30
Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol (2004) 8.21
Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med (2013) 7.98
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med (2006) 6.58
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75
Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol (2010) 3.85
Rapid kidney function decline and mortality risk in older adults. Arch Intern Med (2008) 3.54
Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol (2003) 3.48
Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis (2008) 3.34
Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol (2005) 3.28
Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol (2009) 3.12
25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol (2009) 2.87
Uric acid and long-term outcomes in CKD. Am J Kidney Dis (2009) 2.86
Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int (2003) 2.77
Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med (2007) 2.71
Cardiovascular disease and subsequent kidney disease. Arch Intern Med (2007) 2.65
Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol (2011) 2.56
Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int (2004) 2.38
Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens (2006) 2.34
Relationship of uric acid with progression of kidney disease. Am J Kidney Dis (2007) 2.26
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J (2006) 2.16
Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis (2006) 2.16
C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int (2005) 2.13
Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol (2009) 2.10
The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol (2007) 2.00
Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis (2008) 1.92
Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis (2008) 1.91
Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet (2010) 1.91
Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis (2004) 1.88
Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis (2008) 1.82
The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis (2011) 1.79
Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol (2005) 1.79
Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care (2009) 1.74
Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol (2006) 1.70
Body mass index and mortality in CKD. Am J Kidney Dis (2007) 1.68
Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol (2005) 1.68
Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med (2010) 1.66
Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis (2008) 1.60
Relationship between homocysteine and mortality in chronic kidney disease. Circulation (2006) 1.58
Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int (2010) 1.55
The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis (2008) 1.53
Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens (2006) 1.51
Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis (2005) 1.49
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2011) 1.47
Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis (2008) 1.46
Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens (2004) 1.45
Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars. J Gerontol A Biol Sci Med Sci (2012) 1.45
Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis (2004) 1.43
Filtration markers may have prognostic value independent of glomerular filtration rate. J Am Soc Nephrol (2011) 1.43
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ (2013) 1.43
Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis (2003) 1.42
Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med (2005) 1.41
Cognitive function in chronic kidney disease. Semin Dial (2008) 1.41
Subcortical cognitive impairment in dialysis patients. Hemodial Int (2007) 1.38
Obesity and change in estimated GFR among older adults. Am J Kidney Dis (2009) 1.37
Serum bicarbonate and long-term outcomes in CKD. Am J Kidney Dis (2010) 1.35
Cardiovascular disease and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis (2011) 1.35
Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis (2008) 1.34
Cognitive function in dialysis patients. Am J Kidney Dis (2005) 1.31
Cystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis (2011) 1.30
Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). J Am Coll Cardiol (2009) 1.30
Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60 mL/min/1.73 m(2): the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis (2011) 1.30
Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension (2011) 1.29
Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol (2005) 1.28
Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol (2007) 1.25
Depression and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis (2010) 1.24
Vascular disease, ESRD, and death: interpreting competing risk analyses. Clin J Am Soc Nephrol (2012) 1.23
Anatomic brain disease in hemodialysis patients: a cross-sectional study. Am J Kidney Dis (2012) 1.21
Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant (2009) 1.20
Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol (2011) 1.20
Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis (2006) 1.19
The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis (2005) 1.18
Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant (2009) 1.17
Kidney function and prevalent and incident frailty. Clin J Am Soc Nephrol (2013) 1.16
Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study. Am J Kidney Dis (2010) 1.15
Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol (2005) 1.15
Cardiovascular risk factors in chronic kidney disease. Kidney Int (2005) 1.15
Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes (2010) 1.14
Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis (2006) 1.14
Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med (2007) 1.08
Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol (2011) 1.07
Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol (2009) 1.05
The kidney disease quality of life cognitive function subscale and cognitive performance in maintenance hemodialysis patients. Am J Kidney Dis (2012) 1.04
Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl (2003) 1.02
Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.01
Urinary markers of kidney injury and kidney function decline in HIV-infected women. J Acquir Immune Defic Syndr (2012) 1.01
Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism (2004) 1.01
Management of intradialytic hypertension: the ongoing challenge. Semin Dial (2006) 1.00
Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol (2008) 1.00
Longitudinal association of depressive symptoms with rapid kidney function decline and adverse clinical renal disease outcomes. Clin J Am Soc Nephrol (2011) 1.00
Does hemodialysis hurt the brain? Semin Dial (2011) 0.98
Homocysteine lowering and cardiovascular disease risk: lost in translation. Can J Cardiol (2007) 0.98
Creatinine-based formulae for estimating glomerular filtration rate: is it time to change to chronic kidney disease epidemiology collaboration equation? Curr Opin Nephrol Hypertens (2011) 0.97
Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol (2009) 0.96
Managing dyslipidemia in chronic kidney disease. J Gen Intern Med (2004) 0.96
Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol (2005) 0.95
Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. Am Heart J (2011) 0.95